09 November 2017
Consilium Strategic Communications Sponsors The Alliance for Regenerative Medicine’s Fifth Annual European Advanced Therapies Investor Day
London, 9 November 2017, Consilium Strategic Communications, a global leader in strategic healthcare communications, is proud to sponsor the Alliance for Regenerative Medicine’s Fifth Annual European Advanced Therapies Investor Day, taking place today at 30 Euston Square Place, London.
This one-day, invitation-only meeting provides institutional, corporate, and private investors with exclusive access to this dynamic sector, offering unique, investment-driven insights into the state of clinical and commercial progress and development for advanced therapy medicinal products (ATMP).
The program will aim to address specific questions regarding the outlook for advanced therapies as well as offer insight into how these technologies could impact the standard of care in key therapeutic areas. Attendees will also hear from life science investment experts and analysts covering the sector, as well as presentations by leading European and international advanced therapies companies.
Featured Consilium clients include:
- Kiadis Pharma
- Oxford BioMedica
The full programme can be viewed on the Alliance for Regenerative Medicine’s website: http://eu.arminvestorday.com/agenda/
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications advisory with offices in London and New York. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.